US Bancorp DE Sells 2,143 Shares of HealthEquity, Inc. (NASDAQ:HQY)

US Bancorp DE lowered its position in shares of HealthEquity, Inc. (NASDAQ:HQYFree Report) by 16.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 10,968 shares of the company’s stock after selling 2,143 shares during the period. US Bancorp DE’s holdings in HealthEquity were worth $727,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in HQY. Xponance Inc. boosted its position in HealthEquity by 1.2% during the 4th quarter. Xponance Inc. now owns 12,269 shares of the company’s stock valued at $813,000 after acquiring an additional 147 shares in the last quarter. KLR Investment Advisors LLC lifted its stake in shares of HealthEquity by 4.2% during the 4th quarter. KLR Investment Advisors LLC now owns 5,914 shares of the company’s stock worth $392,000 after purchasing an additional 241 shares during the last quarter. HighTower Advisors LLC boosted its position in HealthEquity by 0.4% during the third quarter. HighTower Advisors LLC now owns 86,940 shares of the company’s stock valued at $6,366,000 after purchasing an additional 340 shares in the last quarter. Mariner LLC grew its stake in HealthEquity by 2.4% in the third quarter. Mariner LLC now owns 14,983 shares of the company’s stock valued at $1,095,000 after purchasing an additional 345 shares during the last quarter. Finally, McGlone Suttner Wealth Management Inc. bought a new position in HealthEquity in the fourth quarter worth about $29,000. 99.55% of the stock is currently owned by institutional investors.

HealthEquity Price Performance

Shares of NASDAQ:HQY opened at $84.84 on Thursday. HealthEquity, Inc. has a twelve month low of $59.02 and a twelve month high of $85.71. The company has a current ratio of 4.76, a quick ratio of 4.76 and a debt-to-equity ratio of 0.43. The company has a market cap of $7.38 billion, a PE ratio of 92.47, a price-to-earnings-growth ratio of 1.39 and a beta of 0.55. The company’s 50 day moving average is $79.64 and its 200 day moving average is $76.12.

HealthEquity (NASDAQ:HQYGet Free Report) last released its quarterly earnings data on Tuesday, March 19th. The company reported $0.50 earnings per share for the quarter, topping analysts’ consensus estimates of $0.42 by $0.08. The firm had revenue of $262.39 million for the quarter, compared to analyst estimates of $258.56 million. HealthEquity had a net margin of 7.71% and a return on equity of 7.88%. On average, sell-side analysts forecast that HealthEquity, Inc. will post 2.12 EPS for the current year.

Insider Buying and Selling at HealthEquity

In other news, Director Evelyn S. Dilsaver sold 32,500 shares of the company’s stock in a transaction dated Tuesday, March 26th. The stock was sold at an average price of $79.29, for a total value of $2,576,925.00. Following the sale, the director now owns 32,123 shares in the company, valued at $2,547,032.67. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director Evelyn S. Dilsaver sold 32,500 shares of HealthEquity stock in a transaction that occurred on Tuesday, March 26th. The shares were sold at an average price of $79.29, for a total transaction of $2,576,925.00. Following the completion of the transaction, the director now directly owns 32,123 shares of the company’s stock, valued at approximately $2,547,032.67. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Jon Kessler sold 33,765 shares of the stock in a transaction on Friday, March 22nd. The stock was sold at an average price of $79.81, for a total transaction of $2,694,784.65. Following the sale, the chief executive officer now directly owns 126,635 shares in the company, valued at $10,106,739.35. The disclosure for this sale can be found here. Company insiders own 2.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Barclays lifted their price objective on shares of HealthEquity from $84.00 to $104.00 and gave the stock an “overweight” rating in a research report on Friday, February 23rd. Barrington Research upped their price target on HealthEquity from $100.00 to $105.00 and gave the stock an “outperform” rating in a research report on Tuesday. Bank of America raised their price objective on HealthEquity from $97.00 to $105.00 and gave the stock a “buy” rating in a research report on Tuesday. BTIG Research upped their target price on HealthEquity from $100.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, March 20th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $92.00 price target on shares of HealthEquity in a report on Tuesday. One analyst has rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat, HealthEquity presently has a consensus rating of “Moderate Buy” and an average price target of $100.58.

Check Out Our Latest Research Report on HealthEquity

About HealthEquity

(Free Report)

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.

Recommended Stories

Institutional Ownership by Quarter for HealthEquity (NASDAQ:HQY)

Receive News & Ratings for HealthEquity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HealthEquity and related companies with MarketBeat.com's FREE daily email newsletter.